Objective: Among postmenopausal women who do not use estrogen therapy (ET), we have previously reported that intensive lifestyle modification (ILS) leads to increases in sex hormoneYbinding globulin (SHBG) and that such increases are associated with reductions in fasting plasma glucose (FPG) and 2-hour postchallenge glucose (2HG). Oral ET decreases FPG and increases 2HG while increasing both SHBG and estradiol (E 2 ). It is unknown if ILS reduces glucose among ET users, if changes in SHBG and E 2 might mediate any glucose decreases in ET users, and if these patterns differ from those in non-ET users.
ILS led to increases in SHBG, which were associated with decreases in both FPG and 2HG. 1 Neither ILS nor metformin led to significant changes in E 2 levels compared with placebo. 1 It has not been reported whether ILS and metformin reduce glucose levels among estrogen therapy (ET) users, and whether SHBG or E 2 is associated with glucose in ET users. The impact of ILS and metformin and their mechanisms of action might differ between ET users and nonusers for several reasons. The protective effects of endogenous SHBG and the detrimental effects of endogenous E 2 might be obscured by ET use, which increases SHBG but also increases E 2 . 6 Randomization to ET compared with placebo has been associated with both decreases in FPG and increases in 2HG. 7<12 The mechanisms through which ET use might affect glucose levels are not known. In studies of ET use, the decreases in FPG persisted after adjustment for adiposity, suggesting that exogenous oral ET reduced FPG through other means such as hepatic gluconeogenesis or hepatic insulin resistance. 7, 12 ET use could increase postprandial glucose through reductions in whole-body insulin sensitivity, 13 but at least one other study showed no association between ET use and insulin sensitivity. 14 Although ET use has declined after the publication of trials demonstrating an increased risk of morbidity, 15 oral estrogens are still commonly prescribed for relief of menopausal symptoms. Therefore, the metabolic effects of ET remain important to examine, and potential mechanisms are relevant to understanding the progression of glucose intolerance in both ET and non-ET users. In the DPP, participants randomized to ILS and metformin had maximal weight loss and reductions in glucose at 1 year after randomization. 5 Changes in glucose were associated with changes in weight and insulin sensitivity. 16 We examined whether postmenopausal women using oral ET at baseline and 1-year follow-up had declines in glucose, and whether DPP treatments induced changes in E 2 and SHBG that were associated with these changes in glucose. We also examined whether these patterns differed among women who did not use oral ET at either baseline or 1-year follow-up ( Fig. 1 ). We hypothesized that interventions would lead to reductions in both FPG and 2HG among ET users; however, unlike in nonusers, changes in SHBG and E 2 would not be associated with these reductions. Finally, we examined whether associations between sex hormone changes and glucose changes persisted after consideration of changes in weight and insulin sensitivity.
METHODS
The characteristics of DPP participants have been reported. 5 Briefly, the DPP inclusion criteria included the following: aged 25 years or older, FPG of 95 to 125 mg/dL, 2HG of 140 to 199 mg/dL after a 75-glucose load, and body mass index of 24 kg/m 2 or higher (Q22 kg/m 2 for Asian Americans). A written informed consent form was obtained from all participants before screening, consistent with the guidelines of each participating center's institutional review board. Eligible participants recruited between 1996 and 1999 were randomly assigned to one of three interventions: 850 mg of metformin twice daily, placebo twice daily, or ILS. The goals of ILS were to achieve and maintain a weight reduction of at least 7% of the initial body weight through consumption of a low-calorie, low-fat diet and to engage in moderate physical activity for at least 150 minutes/week. 5 Weight and waist circumference were measured semiannually, and participants underwent annual oral glucose tolerance test and semiannual FPG test. At the time of randomization, all women completed a questionnaire about their menses, gynecological history (including surgical operations), and exogenous ET use. Medication use was assessed every 6 months.
Women were classified as postmenopausal if they met any of the following criteria: bilateral oophorectomy, lack of menses for at least 1 year without gynecological surgical operation, cessation of menses before hysterectomy, cessation of menses within the past year and aged 55 years or older, and cessation of menses with hysterectomy and aged 55 years or older. For this report, we included women who were postmenopausal at randomization, had an available stored serum sample for E 2 and SHBG measurements, and could be categorized as oral ET users both at randomization and at 1 year follow-up (n = 324) or as non-ET users both at randomization and at 1-year followup (n = 382). Women who used injection, implant, transdermal ET, or transvaginal ET were excluded, as were women who used any ET at baseline but not on follow-up and vice versa. We did not include women enrolled at Native American centers because these women did not originally consent to participate in ancillary studies. Baseline and year 1 assays were performed using the same batched assays. Glucose and insulin were measured as previously reported. 16 Briefly, women were instructed to consume a usual diet, and an oral glucose tolerance test was performed between 7 AM and 11 AM after an overnight fast. Blood was sampled from a vein before (fasting) and 2 hours after a 75-g oral glucose load (Trutol 75; Custom Laboratories, Baltimore, MD). Plasma glucose was measured at fasting state and at 2 hours, and plasma insulin was measured at fasting state. Insulin sensitivity was assessed using inverse fasting insulin levels. 16 Insulin measurements were performed with a radioimmunoassay method using an antiYguinea pig antibody that measures total immunoreactive insulin. The assay is a 48-hour polyethylene glycolYaccelerated method with coefficients of variation of 4.5% for high-concentration quality control samples and 6.9% for low-concentration quality control samples. The coefficient of variation for masked split duplicates in this assay was less than 8.5%. SHBG, follicle-stimulating hormone (FSH), and total E 2 were measured as previously reported. 1 SHBG was measured at Endoceutics (Quebec City, Canada) using ELISA (Bioline) with interassay coefficients of variation of 7.8 and 5.0 at 18.2 and 63.1 nmol/L, respectively. FSH was measured at Endoceutics using ELISA (Bioline) with interassay coefficients of variation of 3.6 and 4.4 at 27.1 and 72.9 mIU/mL, respectively. E 2 was analyzed at Endoceutics using gas chromatography/mass spectrometry. 17 The limit of detection was 3.0 pg/mL for total E 2 , with an interassay coefficient of variation of 17.5 at 4.7 pg/mL. For measurements below the detection limit, values were extrapolated below the lower limit of quantitation using Mass Hunter Workstation software (Agilent, Santa Clara, CA). 1 We also performed sensitivity analyses where we assigned these values the equivalent of the lower limit of detection and found a similar pattern of results (data not shown). Bioavailable E 2 was calculated according to the method described by Sodergard et al 18 (macro courtesy of Frank Stanczyk, University of Southern California), taking the concentrations of total E 2 and SHBG into account and assuming a fixed albumin concentration of 4.0 g/dL.
Statistical analysis
Women who used ET at baseline and on follow-up were analyzed separately from women who did not use ET at baseline and on follow-up. For ET users and nonusers, baseline characteristics were described using percentages for categorical variables and means (SD) for normally distributed quantitative variables. Skewed variables, including insulin levels, FSH, SHBG, total E 2 , and bioavailable E 2 , were logtransformed before comparison. Changes in glucose, SHBG, total E 2 , and bioavailable E 2 were calculated as year 1 level j baseline level. To assess the association between randomization assignment and change in FPG and 2HG as well as change in SHBG and E 2 levels between baseline and 1-year follow-up, we used t tests to compare the levels of change between randomization arms. We also compared log-transformed SHBG and E 2 levels and found a similar pattern of results. Models substituting the homeostasis model assessment of in-sulin resistance for 1/fasting insulin had similar results (data not shown).
To determine whether changes in SHBG, bioavailable E 2 , or total E 2 were associated with changes in glucose apart from changes in adiposity, we created a series of multiple linear regression models, with coefficients obtained by using ordinary least squares. Changes in the aforementioned sex hormones and associations with changes in FPG were examined after adjustment for baseline characteristics (age, race/ethnicity, baseline FSH, and baseline glucose levels), as well as changes in waist circumference and changes in 1/fasting insulin levels. We chose to adjust for weight and not physical activity because, in the DPP, reductions in body mass were the strongest predictor of reductions in glucose levels. 19 Although the level of physical activity was associated with body mass, physical activity was not associated with reductions in glucose after adjustment for body mass. 19 Changes in weight mediated physical activity effects on glucose. We also chose to adjust for 1/fasting insulin because of previous reports suggesting that associations between sex hormones and glucose were mediated by fasting insulin. 2 In the DPP, weight and waist circumference were highly correlated, and we used waist circumference as proxy for visceral adiposity. 20 Similar models that examined associations between changes in sex hormones and changes in 2HG were created. In sensitivity analyses, we examined only women using oral estrogen alone, without progestin. We observed similar results in women using oral estrogen and progestin (data not shown). We also examined models that did not include FSH or baseline glucose levels and observed similar results (data not shown). The SAS analysis system was used for all analyses (SAS Institute, Cary, NC).
RESULTS
The baseline characteristics of the postmenopausal cohort of ET users and non-ET users are shown in Table 1 . Reflecting DPP recruitment criteria, all women were overweight or obese at baseline and had elevated glucose levels. ET users were slightly younger and more often white than nonusers. Among ET users, the most common cause of menopause was oophorectomy, whereas the most common cause of menopause among nonusers was natural or nonsurgical cessation of menses. ET users weighed less and had smaller waist circumferences and lower body mass indexes than nonusers. ET users had lower levels of fasting insulin, FPG, and FSH but higher levels of SHBG, total E 2 , and bioavailable E 2 than nonusers. Of the 324 women who reported using oral estrogen at baseline and on follow-up, 266 women were estrogen-only users at baseline and 58 women used estrogen-progestin; at 1-year follow-up, 258 women were estrogen-only users and 66 women used estrogen-progestin.
Among ET users, there were no significant differences between women randomized to ILS (n = 107), women randomized to metformin (n = 122), and women randomized to placebo (n = 95), except that there were slightly more African-American women in the metformin arm than in the placebo arm (9% vs 5%, P G 0.05). Of the oral estrogens that women reported using at baseline and on follow-up, the most common was conjugated equine estrogens (Premarin), followed by 17A-estradiol (Estrace), esterified estrogens (Estratab, Menest), and estropipate (Ogen, Ortho-Est). Of the 211 women who had hysterectomy, none was using progestin at baseline or on follow-up. Of the 113 women who did not report hysterectomy, all were using progestin at baseline and on follow-up. Among nonusers, there were no significant differences between women randomized to ILS (n = 133), women randomized to metformin (n = 122), or women randomized to placebo (n = 129), except that women randomized to metformin had slightly lower FSH levels than women randomized to placebo (51.5 vs 59.3 IU/L, P G 0.05).
Among both ET users and nonusers, women randomized to ILS and metformin had declines in waist circumference compared with placebo (P G 0.01 for all comparisons). The association between randomization arm and decreased waist circumference persisted after adjustment for age, race/ethnicity, and FSH levels (results not shown). Changes in glucose levels between baseline and year 1 by randomization arm are presented in (Fig. 2) . Among ET users, women randomized to ILS had significant reductions in FPG (P G 0.01) and 2HG (P G 0.01) compared with placebo. Among ET users, women randomized to metformin had significant reductions in FPG (P G 0.01) but not 2HG (P = 0.56) compared with placebo. This pattern of results was similar across different types of estrogen (results not shown). Among nonusers, women randomized to ILS had significant reductions in FPG (P G 0.01) and 2HG (P = 0.03) compared with placebo, but women randomized to metformin did not have significant reductions in FPG (P = 0.20) or 2HG (P = 0.50) compared with placebo. These associations between randomization arm and glucose levels persisted after adjustment for age, race/ethnicity, and FSH levels (results not shown).
Changes in SHBG, total E 2 , and bioavailable E 2 between baseline and year 1 by randomization arm are presented in (Fig. 3) . Among ET users, women randomized to ILS or metformin did not have significant changes in SHBG (P = 0.11 and P = 0.16, respectively) or total E 2 (P = 0.46 and P = 0.15, respectively) compared with placebo. However, women randomized to ILS (P = 0.046) and metformin (P = 0.042) did have significant reductions in bioavailable E 2 compared with placebo. Among nonusers, women randomized to ILS had significant increases in SHBG compared with placebo (P G 0.01), but women randomized to metformin (P = 0.58) did not have significant changes in SHBG. Among nonusers, women randomized to ILS or metformin did not have significant changes in total E 2 (P = 0.36 and P = 0.10, respectively) or bioavailable E 2 (P = 0.54 and P = 0.11, respectively). This pattern of associations between randomization arm and SHBG and E 2 levels remained similar after adjustment for age, race/ethnicity, and FSH levels (results not shown). Table 2 shows the associations of changes in SHBG, total E 2 , and bioavailable E 2 with changes in glucose. Among ET users who were randomized to ILS, there were no associations between changes in SHBG or E 2 and changes in FPG or 2HG. Among ET users who were randomized to metformin, reductions in bioavailable E 2 were associated with reductions in 2HG. This association persisted after further adjustments for changes in 1/fasting insulin (P = 0.04), suggesting that the association between bioavailable E 2 and 2HG was not mediated through adiposity or 1/fasting insulin. However, overall, significant reductions in 2HG among metformin users versus placebo users did not occur (Fig. 2) .
Among nonusers (Table 2) , increases in SHBG were associated with declines in FPG and 2HG after adjustment for waist circumference, and these associations persisted after further adjustments for change in 1/fasting insulin (P G 0.05 for both associations). Among nonusers, declines in total E 2 and bioavailable E 2 were associated with declines in FPG, and this association persisted after further adjustments for change in 1/fasting insulin (P G 0.05). However, overall, significant reductions in total E 2 and bioavailable E 2 among women randomized to interventions versus placebo did not occur (Fig. 3) . Among nonusers, changes in E 2 were not associated with changes in 2HG. When we examined the nonusers, excluding women who had undergone oophorectomy, ILS still led to declines in SHBG compared with placebo (P G 0.01), and declines in SHBG were still associated with significant declines in FPG (P = 0.01) although the association with declines in 2HG was attenuated (P = 0.14).
DISCUSSION
In a secondary analysis from the DPP, a randomized placebocontrolled trial, we observed that ILS led to reductions in both fasting glucose and postprandial glucose among ET users and nonusers. However, ILS effects on SHBG and E 2 differed between ET users and nonusers, and SHBG and E 2 had associations with glucose that differed by ET use. These findings suggest that the roles of SHBG and E 2 in influencing glucose levels depend on whether these hormones are exogenous or endogenous. Among ET users, ILS did not change SHBG, and SHBG was not associated with changes in FPG or 2HG. In contrast, among nonusers, ILS led to increases in SHBG that were associated with decreases in glucose even after adjustment for adiposity and insulin sensitivity. Among ET users, ILS led to significant reductions in bioavailable E 2 compared with placebo, although these changes were not associated with declines in glucose. Among nonusers, ILS did not change E 2 levels, although decreases in E 2 were associated with decreases in FPG. Among ET users, the declines in FPG observed among metformin users did not seem to be associated with changes in SHBG, bioavailable E 2 , or E 2 . Among nonusers, metformin had minimal impact on glucose levels. The relationship between E 2 , SHBG, and glucose was dissociated in ET users compared with nonusers, even as interventions were still effective in reducing glucose in both ET users and nonusers.
Our findings are notable for several reasons. First, we found that lifestyle modification can still reduce postprandial glucose levels in the context of ET use. In the Postmenopausal Estrogen/Progestin Intervention Study, randomization to ET was associated with significant reductions in FPG and fasting insulin, but with elevations in 2HG. 7 The effects of exogenous estrogen on 2HG were not mitigated by lifestyle behaviors. 7 Our results may have differed in that the DPP examined a glucose-intolerant population, and any additional negative effects of ET on glucose tolerance may not have been as apparent. Also, women were randomized to lifestyle change, which in turn resulted in significant reductions in weight and glucose compared with placebo. Second, we found that SHBG was not associated with reductions in glucose levels in ET users, although SHBG was associated with reductions in both FPG and 2HG in nonusers. 1 Among nonusers, hepatic steatosis may be a common antecedent of SHBG and glucose, or SHBG may influence hepatic glucose production apart from steatosis. 21 ET use itself was associated with almost a tripling of SHBG levels, and it is possible that further increases in SHBG resulting from ILS had minimal effects on glucose levels. Third, we found that bioavailable E 2 declined among ET users randomized to ILS and metformin compared with placebo, although we did not observe these changes among nonusers. Baseline E 2 levels were lower among nonusers compared with ET users, and it is possible that further reductions in bioavailable E 2 were minimized by these low levels. However, among ET users, these reductions in bioavailable E 2 were not significantly associated with reductions in glucose. Even though reductions in bioavailable E 2 were associated with reductions in 2HG among metformin users, metformin users did not have statistically significant declines in 2HG overall.
To our knowledge, no reports have examined the impact of metformin on postmenopausal women without polycystic ovarian syndrome. Among ET users in this report, metformin had favorable effects on FPG with less marked reductions in 2HG. Metformin effects on FPG did not seem to be mediated by metformin effects on E 2 levels because total E 2 and bioavailable E 2 were not associated with FPG among ET users. Thus, sex hormone effects do not seem to be an important pathway for metformin effects on glucose among postmenopausal women using exogenous estrogen. Among non-ET users, metformin effects on FPG and 2HG were minimal, consistent with other DPP studies demonstrating a reduced effectiveness of metformin in older populations. 22 Although metformin has decreased sex steroid levels in women with polycystic ovarian syndrome, 23 sex steroid levels, including E 2 , were higher in women with polycystic ovarian syndrome than in the postmenopausal women in this report. Thus, for different reasons compared with ET users, sex hormones do not seem to be an important pathway for metformin effects on glucose among postmenopausal women not using estrogen.
One of the limitations of this report is that women were not randomized to ET use and lifestyle intervention. For optimal assessment of the interactions between ET use and glucose reduction interventions, randomization to ET use and to ILS, metformin, and placebo would have been necessary, although such a study is unlikely to be conducted. Because ET use was strongly associated with surgical menopause, particularly bilateral oophorectomy, this would have required additional adjustment for indications of surgical menopause, which would have been logistically challenging. Therefore, despite uniform inclusion criteria for weight and glucose elevations, ET users differed from nonusers in demographic characteristics, anthropometrics, and metabolic measurements, and these characteristics and other unmeasured characteristics may have led to the different roles of E 2 and SHBG in glucose changes. It is possible that residual confounding from adiposity or insulin sensitivity occurred because the proxy measures used were not direct measures. ET was assessed via recording of medications and may have overestimated or underestimated ET use. Although overweight and obese women tend to have lower FSH levels than normal-weight women in postmenopause, 24 some of the nonestrogen users may have been misclassified as postmenopausal as opposed to premenopausal, and this in turn may have increased or decreased observed associations. Although the analyses did not differ when we examined estrogen users only versus estrogen-progestin users, progestin type may have atered the hormonal milieu. Finally, the women studied were already overweight and glucose-intolerant, and our results may not extend to healthier women. The strengths of our report include its randomized design for glucose-reducing interventions, interventions that successfully reduced waist circumference, and measurement of postchallenge glucose and fasting glucose.
CONCLUSIONS
Our hypothesis-generating report suggests that glucoselowering interventions might act via different mechanisms in estrogen users and nonusers, that glucose reduction interventions are effective among ET users, and that the roles of E 2 and SHBG in glucose change differ depending on whether women use ET. Intervention-associated increases in SHBG may be less important among women who use ET in part owing to significant elevations in SHBG associated with ET. Although there are reductions in bioavailable E 2 among ET users with lifestyle change, the clinical significance of this finding is not clear. Metformin may be less effective in reducing postchallenge glucose among postmenopausal women than is ILS, but this effect is observed among nonusers and ET users and is likely not caused by adverse effects of ET.
